Phaseline

Companies › Calluna Pharma

Calluna Pharma: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Respiratory; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
CAL101
LPIN1 inhibitor
LPIN1Phase 2Idiopathic Pulmonary FibrosisNov 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06736990CAL101Phase 2Idiopathic Pulmonary FibrosisRespiratoryNov 2026

Targets

LPIN1 (1)

Companies with the same targets

–

Companies built like this

Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA Aimmune Nestlé Health Science US R&D Vicore Pharma SpliSense ReCode Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.